Response to cilta-cel. Response among responders (A) and in all patients with previous exposure to antibody-drug conjugate (ADC) (B) or BsAb (C). Classification is based on the last anti−B-cell maturation antigen therapy used if patients received >1 therapy. NE, not evaluable; SD, stable disease. ^†Patient was treated with ADC for 1 day. ^‡Patients with extramedullary plasmacytomas. ^§Patient was treated with 2 different ADCs. ^||Patient received BsAb first and ADC later.